• First mover in plant-to-bloodstream niche
• Proprietary technology improving bioavailability of orally ingested cannabinoids
• Two distinct consumer product brands: ViPova™ and Lexaria Energy

With the recreational market set for legalization on July 1, 2018, Canada’s cannabis industry is experiencing a high that is catalyzing innovation in the biosciences sector. Pioneering biopharmaceutical companies there and in other developed countries are working to develop a variety of healthful products based on their research into cannabinoids. As a result, investment capital flow to “plant-to-bloodstream” companies is expected to swell just as it has been doing for “seed-to-plant” companies for some time, and innovative British Columbia-based outfit Lexaria Bioscience Corp. (OTCQB: LXRP) (CSE: LXX) will, undoubtedly, be buoyed by this development, since it is a “first mover” in this space.

Lexaria is one of that new breed of “plant-to-bloodstream” companies exploring ways to make the health benefits of cannabinoids more accessible. The company has developed technology that delivers the nutriments of hemp oil in a novel and more effective way. Many hemp products on the market are simply mixtures of hemp oil with other ingredients. However, Lexaria’s patented methodology infuses organically sourced hemp oil into the molecules of other substances, such as lipids, which, as it turns out, form the basis of the human endocannabinoid system. Consequently, the body better absorbs products employing the technology.

In general, the human gastrointestinal tract does not handle cannabinoids effectively, and much of what is ingested is simply excreted by the body. In addition, realizing this, many users of edible products will try other cannabinoid delivery methods, such as smoking, with their attendant evils. For those smoking cannabis, there is more peril in the smoking than in the cannabis.

Lexaria applies its innovative delivery technology to its product line, which consists of two distinct brands: ViPova™ and Lexaria Energy. ViPova™ is a delicious Chinese black tea from the province of Yunnan, made from hemp oil-infused within dried evaporated non-fat milk. Introduced in January 2015, the tea is available in a host of varieties and flavors. The ViPova range runs from 8- to 32-bag portions, and varieties include Decaf English Breakfast, Earl Grey, Herbal Bengal Chai, Herbal Cherry Black Tea, Herbal Masala Chai, Low-Caf Organic Evening Green Tea and ViPova Light.

If you are a couch potato, Lexaria Energy products are not for you. The Lexaria Energy line is meant for those with busy, active lifestyles. Under this brand, the company has launched a hemp oil-infused protein bar called the Lexaria Energy Bar, which, as its name suggests, provides reserves of energy you can draw on to go the extra mile.

Lexaria is not resting on its laurels with these groundbreaking developments. In February 2017, it signed a master collaborative research agreement with the National Research Council of Canada (NRC) to investigate technical aspects and new opportunities associated with bioavailability enhancement of lipophilic active ingredient compositions. Lexaria believes its patented technology can be applied to the delivery of nicotine, vitamins, analgesics and a variety of other substances.

In May 2017, the company announced that its 50%-owned joint venture subsidiary, Ambarii Trade Corporation (Ambarii) had entered into a Letter-of-Intent (LOI) with Naturally Splendid Enterprises Ltd. (TSXV: NSP) for the production, sale and distribution of Ambarii’s proprietary sublingual full spectrum hemp CBD tablets in Japan and South Korea. Ambarii CBD Tablets offer a consistent, quick dissolving dose of full spectrum hemp oil, combined with the powerful antioxidant properties of pterostilbene.

Lexaria Bioscience Corp., formerly Lexaria Corp., is a food sciences company. The company focuses on the delivery of cannabinoid compounds procured from legal, agricultural hemp, through gourmet foods based upon its infusion technologies. Its food sciences activities include the development of its nutrient infusion technologies for the production of super foods, and the production of food products under its two consumer product brands, ViPova and Lexaria Energy. Its technology is developed to aid absorption and bioavailability of various payload molecules, including cannabinoids, such as cannabidiol (CBD) and tetrahydrocannabinol (THC).

For more information, please visit www.lexariaenergy.com

• SING targets the large and rapidly growing multi-billion dollar retail cannabis sales industry
• New agreement provides efficient and easy-to-apply solution to critical unmet need
• Purchasing model opens door to additional opportunities for investor profit in cannabis

An iPod interview with SinglePoint president Wil Ralston (http://dtn.fm/S8exI) covers the significant advantages that the company’s recently announced joint venture with First Bitcoin Capital Corp. (OTC: BITCF) represents for the cannabis industry. In a study of 20 U.S. jurisdictions by Greenwave Advisors, legal marijuana represented $6.5 billion in retail sales by May 2017, as reported by Forbes (http://dtn.fm/3XOmc). At the current level of growth, industry experts project that, by 2021, the legal cannabis retail market may grow to $30 billion. Marijuana is legal in many states for either medicinal and/or recreational purposes. The challenge, therefore, isn’t market reach, but restrictions at the federal level, particularly in the banks. Federal guidelines restrict transactions related to cannabis, but SinglePoint (OTC: SING) has found a way around this by forming its first joint venture – with First Bitcoin Capital Corp. (OTC: BITCF).

The joint venture allows dispensaries and other businesses to use Bitcoin payments rather than traditional cash transactions. This combination of SinglePoint’s acquisition and distribution history and Bitcoin’s payment system and block chain technology is already serving the cannabis industry well. The system is being used to enable customers to visit dispensaries and make purchases using a debit or credit card. The transaction goes through Bitcoin first, with the dollar conversion completed afterward. A streamlined purchasing model is expected to help smooth out the supply chain process, so shareholders and investors in SinglePoint can find additional opportunities to profit and contribute to the fast-growing cannabis industry.

The value of Bitcoin has gone up 236 percent in just one year. It is also recognized as a legal currency in Japan. Being adopted on a wide scale, the technology can also allow SING to reach a global market. In the iPod interview, company president Wil Ralston reveals that there are now 290,000 retail stores in Japan accepting Bitcoin payments. In the U.S., payments can be converted to U.S. currency, according to Ralston, without waiting for the banking system to accept the legal status of cannabis. Ralston said he’s been “waiting for the banks to open up, but we don’t have to wait any longer with this new product. I think this is one of the most exciting things to happen in SinglePoint’s lifespan.”

In addition to a blockchain supply chain management solution, the joint venture is incorporating initial coin offerings through First BitCoin Capital. SinglePoint has also launched SingleSeed.com, which will provide web design and online marketing services to cannabis dispensaries. It’s expected to soon complete a variety of acquisitions as well, leading to anticipated growth in revenue.

The company’s strategy has opened up a vast network of financial and technology partners. This has enabled it to expedite the execution of deliverables. Plus, the cannabis and other high-risk markets don’t have to wait for changes in federal banking guidelines. At the rate Bitcoin payments are catching on, cannabis dispensaries can adopt a point-of-sale solution that allows them to meet growing demand.

In fact, adopting the technology of First Bitcoin Capital and SinglePoint only requires downloading an application onto any point-of-sale machine. Learn more by going to www.SinglePoint.com or www.SingleSeed.com.

Let us hear your thoughts: SinglePoint, Inc. Message Board

• LED lighting producer and leading indoor plant growth solutions provider
• Focused on efficiencies for the legal cannabis industry
• Website is now SEO-optimized, providing an easier way to order product

Future Farm Technologies, Inc. (CSE: FFT) (OTCQB: FFRMF) has fully updated and SEO-optimized its e-commerce website (www.LEDCanada.com) in response to rising consumer demand for LED grow lights. The new and expanded site has gone live, and the LED product line can be viewed on LEDCanada.com.

The site now contains a number of social media buttons for Facebook, Twitter, and Pinterest. The LEDCanada.com website will be updated with the newest content from the company, such as blogs, client announcements, newsletters, and specific stories about client successes.

Based in Vancouver, the company is a Canadian LED manufacturer of residential and commercial lighting, fixtures, lamps, and more. It is also a leading indoor plant growth technology company specializing in LED lighting, mobile applications, and vertical farming solutions for the legal cannabis industry.

“Our goal with the updated website is to provide our customers with an easier way to order and learn about Future Farm’s LED grow light services and solutions by allowing them to browse information and order lights based on their own preferences,” William A. Gildea, chairman and chief executive officer of Future Farm, stated in a news release. “The website is now optimized for mobile devices, is interactive, and provides better access to information about LEDCanada.”

For more information, visit www.FutureFarmTech.com

• North American business up 40 percent in Q1
• Track record of phenomenal domestic growth with international growth plan in place
• Zach’s pegs NETE at $3.12 per share once profitable

Currently trading at 65 cents a share, Zach’s Small Cap Research just pegged Net Element (NASDAQ: NETE) at $3.12, five times current market value, once it reaches profitability (http://dtn.fm/9vNVT). The highly respected research firm noted that Net Element’s U.S. business growth was up a phenomenal 40 percent in the first quarter, while the company’s overseas operations and expansion were currently dragging down growth. However, global expansion has been a cornerstone of Net Element’s long term growth plans.

Growth, the elixir of Wall Street, is no stranger to Net Element. Just last year, the company was recognized by the South Florida Business Journal as one of the fastest growing technology companies in the United States, and, in 2012, the company’s Unified Payments division was named the fastest-growing private company in America by Inc. Magazine. To become an industry leader, investing, opening and expanding into new markets is imperative to sustain growth trajectories over time.

A technology-driven mobile payments and transactional services company, Net Element’s products and services include mobile payments, value-added services, marketing solutions and business analytics. Through its wholly owned group of companies, Net Element’s global divisions support electronic payments acceptance in an omni-channel environment spanning across point-of-sale, e-commerce and mobile devices. The company provides turn-key services, including the technology and services required for cashless transactions, to small and medium-sized businesses throughout the United States and in select international markets.

Known for its dynamic marketing efforts, Net Element’s North American Unified Payments division continued its strong growth in Q1 2017 as the company added a record 1,500 merchants to its customer base. The company is aggressively adding new North American customers, and rapid customer acquisition is continuing into Q2.

Net Element’s international game plan is to spur global growth where it already has a substantial footprint by leveraging its omni-channel platform to deliver flexible offerings to select emerging markets with diverse banking, regulatory and demographic conditions, such as the UAE, Kazakhstan, Kyrgyzstan and Azerbaijan. Net Element has already launched initiatives is these locations.

Given Net Element’s historic track record of phenomenal domestic growth, there’s no reason to doubt the company’s ability to grow internationally. Once Net Element kicks revenue in its international markets into high gear, profitability should be around the corner and Zach’s target of $3.12 per share should easily be in reach.

For more information, visit www.NetElement.com

• Launched world’s first Chinese language online CBD health products store
• Launched world’s first Chinese language mobile cannabis navigation app
• Positioned to become first company in China to use CBD oil in treating epilepsy and Alzheimer’s

Pursuing its aim of becoming the leading publicly traded Chinese medical marijuana company, ChineseInvestors.com, Inc. (OTCQB: CIIX) continues its focus on investing in distribution and R&D of cannabidiol-based (CBD) medicines and health products targeted at Chinese-speaking clients throughout the world.

Marijuana use is currently illegal in China, but cannabis-based oils, including hemp-based CBD, are legal, giving CIIX access to a market of almost two billion potential customers in that country. CIIX is also expanding its footprint to other countries and recently incorporated CBD Biotechnology Inc. in British Columbia, Canada, which will focus on R&D and distribution of health products, including hemp-based CBD, food and beverage products there.

Additionally, CIIX officially launched a CBD online store, ChineseCBDoil.com, in December 2016 in the free-trade zone of Shanghai, China. The site went live on January 31 and is the very first CBD health products Web store to be launched in the Chinese language, offering various CBD nutritional products, such as soft gels, capsules and concentrates. The company further plans to market a line of nutrition and food products through a brick-and-mortar store in San Gabriel, California — a predominantly Chinese-speaking area and the company’s home market (http://dtn.fm/HcS2S).

Concurrent with the launch of ChineseCBDoil.com, CIIX also launched the very first Chinese language mobile cannabis navigation app, which is a Yelp-style social media app containing a database of cannabis dispensaries and marijuana strains. The app also features a platform for reviewing and discussing cannabis products, maps showing marijuana dispensary locations, and summary reports of cannabis businesses in Los Angeles and other large cities. This app has already been approved by the Apple store.

CIIX’s other cannabis-related endeavors include striving to become the very first company in China to employ CBD oil as a treatment to relieve suffering for epilepsy and Alzheimer’s patients. The company plans to continue studying CBD oil’s efficacy as a treatment for these diseases and intends to invest in CBD drug R&D enterprises, with an end goal of developing a variety of CBD drugs to treat epilepsy and Alzheimer’s.

For more information, visit the company’s website at www.ChineseInvestors.com

Let us hear your thoughts: ChineseInvestors.com, Inc. Message Board

• A 1,000-fold increase in the Canadian cannabis oil extraction market is expected, with growth from C$1 million in 2015 to an expected C$1.7 billion by 2020
• The Canadian market is expected to see a conversion rate of 45 percent, which is similar to trends in Colorado, based on a Mackie Research Capital study
• The Government of Canada expects to fully legalize marijuana nationwide on or before July 2018

Investors have had their eyes on Algae Dynamics Corp. (OTCQB: ADYNF), which has partnered with various Canadian universities (including the University of Waterloo and Western University) for access to research and to boost its cannabis extraction expertise. The company is now positioned to serve the medical and recreational marijuana markets. However, many are surprised to learn that, as legalization of recreational marijuana is set for July 2018, Charles Sousa, Ontario’s finance minister, has warned of a possible supply shortage.

The company has had at the core of its product development strategy the extraction of Omega-3 fatty acids from certain strains of algae with high concentrations of DHA, which is an important nutrient for brain, eye, and heart health, as well as the creation of various associated nutraceutical products. In light of the many demonstrated health benefits of other botanical oils, most notably cannabis oil, the company has developed a strategy aimed at developing new products combining the health benefits of algae and cannabis oils.

In a Bloomberg Politics article (http://dtn.fm/r2Ne5), an analyst suggested a supply shortage could give the government an excuse to delay the country’s marijuana program, even as the cannabis oil extraction market grows toward the billion-dollar mark. Government officials, however, have made it clear they want a supply that’s able to accommodate demand to bring down organized crime and illicit drug use. The initial plan is expected to allow sales of cannabis online and via mail.

The reasons for a potential shortage include difficulty in stocking enough inventory nationwide, expanding patient lists, and producers selling out of strains or refusing to take on new clients. In Canada, the number of registered medical marijuana users tripled in one year, and the medical market is already seeing shortages. Health Canada announced in May that it would expedite the license approval process. New licenses have been issued, but it can take a year or more for businesses to build up production. Recent studies have shown a 45 percent conversion rate (users of dry marijuana switching to cannabis oil products) in Colorado, which is anticipated in Canada as well. Licensing and expertise will be needed to meet this demand.

Despite uncertainties, demand and research and development in the cannabis market continue to surge. As Algae Dynamics aims to be the leader in cannabis oil research in Canada, it continues to pursue the compound as a treatment for conditions such as colorectal, breast, pancreatic, and prostate cancers, and for other conditions such as post-traumatic stress disorder, schizophrenia, anxiety, and depression. The company itself will submit a licensing application to Health Canada, so it can produce medical marijuana and sell cannabinoid-derived products. Its knowledge and cultivation know-how enables production of an algae biomass that is free of contaminants and high in healthy Omega-3 fatty acids.

The management, fundraising, process, and commercialization experience of the Algae Dynamics team has positioned the company for rapid growth. Despite the threat of a legalized marijuana supply shortage, the company is working hard with researchers, developers, and investors in a market that encompasses all of Canada and that extends well beyond the country’s borders.

For more information about the company’s research efforts and development process, go to www.AlgaeDynamics.com

Let us hear your thoughts: Algae Dynamics Corp. Message Board

• HCPA (subsidiary) possesses the technical expertise to source, implement, and distribute at-profit reclaimed water.
• AES (subsidiary) provides off the shelf and custom designed treatment technologies across customer base that contribute to HCPA’s business model of low-cost treatment and distribution.
• Gilbert (subsidiary) eyeing investment opportunities within the Marcellus and Utica regions (PA, OH, and WV areas). With Gilbert as an owner and producer of energy sources in the region, it and each competitor is a potential customer for AEPI services.

Converde Energy USA, Inc. (OTC: XFUL), d/b/a American Energy Partners, Inc., may not be walking on water, but its management has created a business model that looks likely to pull off a miracle. Based in Pennsylvania, American Energy Partners, Inc. (AEPI) and its subsidiaries together comprise an integrated vertical that sources, scrubs, and supplies water to mining, oil and gas, power and other industrial concerns. Now producing half of oil output and two-thirds of gas output in the U.S., fracking is an industry that undoubtedly will require large volume providers like AEPI to keep its head above water.

Water plays an essential role in hydraulic fracturing (fracking), and a typical well requires about 4.4 million gallons. That’s the amount used by 11,000 American families every day. Most of that water (63%) comes from surface sources such as rivers; another substantial amount (20%) is purchased from public water utilities that source surface supplies and wells; almost as much (15%) is recycled treated flowback water from previously fracked wells; while the rest (2%) are the ‘active fracking ingredients’, consisting of proppants and chemicals. Proppants are the suspensions of sand that keep bedrock fissures open, allowing gas and oil to flow out. With about 4,475 locations still to be drilled between the Marcellus and Utica regions of Pennsylvania and Ohio, AEPI’s future as a water provider looks rosy. “The Utica and Marcellus shale natural gas plays based respectively in Ohio and Pennsylvania have provided 85-90% of U.S. shale gas production growth since start of 2012,” according to Forbes (http://dtn.fm/L2LEp).

AEPI’s triple play, comprising Hydration Company of PA (HCPA), American Energy Solutions, LLC (AES) and Gilbert Oil & Gas Company (Gilbert), integrates proprietary interests in water sources, design and treatment solutions, and marketing opportunities and business alliances.

The HCPA model implementation begins when hydrological studies are carried out to locate the largest pools of non-potable water, i.e., water that is not safe for drinking. Negotiations are then initiated with the current owners to gain access to these pools. After additional hydrological and engineering studies are performed and the required permits obtained, a filtration system is installed. Lastly, a dynamically-adjustable, turn-key platform goes online, allowing HCPA to distribute as required.

HCPA’s hands-on execution is backed up by sister subsidiary American Energy Solutions (AES). AES provides the technologies that HCPA uses to implement its strategy of providing cost-effective water treatment and distribution. AES plans to develop an in-house team with the ultimate aim of building market share in treatment technologies and the design of distribution methodologies. Meanwhile, AEPI plans to use Gilbert’s broad industry valuation experience to source drilling, operating, and partnership opportunities in the upstream oil and gas space. With so much going for it, AEPI seems to be offering investors in need of comfort a bridge over troubled water.

For more information, visit the company’s website at www.AmericanEnergy-Inc.com

Let us hear your thoughts: Converde Energy USA, Inc. Message Board

• ORHub is a cloud-based health care software that can help medical providers achieve cost efficiencies of 20-40% and drive closure of reimbursement gaps
• In real time, through Azure intelligence and analytics, it can analyze procedures, offer predictive analysis, and enable efficient procurement for hospital administrators
• It can develop fair pricing on bundled payments for providers and payers

ORHub, Inc. (OTC: ORHB), a health care software-as-a-service company, is primed to play an important role in delivering both cost reduction and actionable resource analytics tools in surgeries such as spinal, hip, knee, and cardiac catheter procedures, offering greatly improved resource allocation, real time monitoring of surgery, and predictive analysis using cloud-based software that delivers fact-based cost targets. The result: ORHub can help achieve cost reductions of from 20-40% in health care.

The value of this revolutionary system is illustrated by the experience of the Hoag Orthopedic Institute (HOI) in using ORHub to advance orthopedic care (http://dtn.fm/31EYx). HOI is successfully using the system to improve teamwork, automate manual processes, and better understand resource allocation in its spinal surgeries. The system, which runs on the Microsoft Azure platform, can play a critical part in achieving value-based models of health care. In spinal surgeries, it enables hospital administrators, through Azure intelligence and analytics, to offer real time digital review and reconciliation. In can generate accurate records which can be sent electronically to multiple entities, including medical device companies, hospital procurement, materials management, and billing departments. ORHub is on the frontline of new health care IT delivery. It is seen as both agile and scalable.

Wesley Mitchell, chief technology officer at ORHub, said, “When we have 50,000 procedures in the system, we can start to effect change in the healthcare world. That includes introducing predictive analysis that hospitals can use to anticipate what resources are necessary for a given type of procedure. This can also help healthcare providers and payers coordinate fair pricing on bundled payments.”

Mitchell added that the introduction of ORHub’s software into the medical field could result in cost reductions of from 20-40%. That’s significant, because U.S. health care costs are at more than $3 trillion annually, or 17% or the American GDP, per ORHub calculations.

“If we can achieve that with the cost of surgeries across the U.S. health system, that equates to USD $250-$350 billion saved every year. That’s greater than the gross domestic product of Finland,” Mitchell said.

He added that he started the project after being contacted by a surgeon about wanting software to help analyze resource allocation for surgical procedures. According to ORHub’s research, hospitals spend between 48-50% of their overall revenue on surgery. Mitchell’s interest was piqued, and the project was initiated.

For more information, visit the company’s website at www.ORhub.com

Let us hear your thoughts: ORHub, Inc. Message Board

• Compliant, protective, and blast-proof products can reduce damage at federal, state, and local facilities
• Barriers, revetments, fuel tank jackets, and blast protection equipment are suitable for customers in commercial and military market sectors
• New products or retrofits are available to customers requiring powerful blast protection and fire suppression systems

Blastgard International, Inc. (OTC: BLGA) is a manufacturer of proprietary blast mitigation products that meet the requirements of the Support Anti-terrorism by Fostering Effective Technologies Act of 2002 (SAFETY Act). Used by commercial, law enforcement, government, and military customers, the company’s blast-resistant and fire-suppressing materials provide the anti-terrorism protection specified under the Department of Homeland Security’s SAFETY Act. The legislation calls for technology that can be immediately deployed at public and private facilities, limit liability of anti-terrorism technology providers, and prevent a large-scale loss of life and economic impacts.

In addition, Blastgard’s products have been approved by the General Services Administration (GSA). This qualification streamlines procurement in that several federally-mandated contracting requirements are met. Being approved by the GSA means products such as BlastWrap® are differentiated in the market, so public and private agencies can have improved access to them. BlastWrap is on the DHS’s “Approved Products List for Homeland Security” and provides protection against strong explosions, ballistic materials, and fragments. Working indoors and outdoors, in wet/dry conditions and vented/unvented locations, it can protect property and people against solid explosives and fires caused by flammable liquids.

BlastWrap materials can be used in the cargo holds and containers of commercial aircraft, as building walls (to protect against vehicle bombs), and around fuel tanks to suppress explosions and fireballs. They have also been used on naval vessels and merchant ships, minimizing the impact from mines, torpedoes, and cruise missiles. Suitable as dividers on aircraft, ships, and offshore platforms to suppress fuel mist explosions and fireballs, the products have also been used in explosives manufacturing and handling facilities, propellant manufacturing plants, and fireworks plants as partitions and separators. Also, the company’s products have been implemented in underwater applications and entertainment industry sound stages.

The company also manufactures the Blastgard MTR Series of trash receptacles. These triple-wall containers can withstand improvised explosive devices, their fragments, and fires. Weatherproof and corrosion-resistant, the 35-gallon capacity receptacles can be customized with colors, artwork, logos, and powder coating. Each unit can resist over 4,000 pounds of horizontal and vertical force.

Usable in just about any industry, Blastgard’s products are in demand at a time when terror attacks occur on a regular basis. Recent events in Europe, including a bomb explosion at the Brussels Central train station on June 20 (http://dtn.fm/Rlxb8), warrant methods of protecting personnel and civilians with equipment that can withstand explosions and fires. The incident occurred just months after terror attacks killed over 30 people in the city. Additional events and heightened alerts demonstrate the need for protection when such potentially devastating incidents cannot be avoided.

For more information about BlastGard International, BlastWrap technology, and blast-proof products for commercial, military, law enforcement, and government segments, go to www.BlastgardIntl.com

Let us hear your thoughts: BlastGard International, Inc. Message Board

• Alzheimer’s is the most ominous and expensive disease in the U.S.
• IGC is the first and only NYSE MKT-listed pharmaceutical company to develop cannabis-based Alzheimer’s therapies
• IGC’s patent pending phytocannabinoid therapies to enter clinical trials for potential Alzheimer’s breakthrough

A pioneer in the development of innovative cannabis-based combination therapies, India Globalization Capital (NYSE MKT: IGC) is creating new classes of phytocannabinoid pharmaceuticals with broad therapeutic applications for both humans and animals. IGC’s pipeline of patent pending therapeutics include treatments for pain, cachexia, neurologic disorders, Parkinson’s and Alzheimer’s disease. IGC plans to enter clinical trials this year on its primary pipeline of four major therapeutics that address large market maladies. These trials include a potential cannabis-based blockbuster treatment for Alzheimer’s, America’s most ominous and expensive disease.

Alzheimer’s disease has no cure, no means of prevention and no long-term disease-modifying treatments. It’s a fatal, progressive brain disease that slowly destroys memory and thinking skills. It’s the third-leading cause of death in the U.S., following cancer and heart disease. More than 5.3 million Americans and over 46 million people worldwide are currently suffering from Alzheimer’s, and, frighteningly, this number is expected to triple within a few decades. Alzheimer’s is also the most expensive disease in the nation. In 2016, costs totaled $236 billion for the U.S., and global costs exceeded $600 billion. These figures will skyrocket if the disease continues unchecked.

Bolstering its portfolio of patent pending cannabis-based pharmaceuticals, IGC recently acquired exclusive rights to a novel THC-based treatment for Alzheimer’s disease from the University of South Florida (http://www.igcinc.us/alzheimers-disease/). Under the definitive license agreement with the university, IGC is the exclusive licensee of a patent filing for the use of tetrahydrocannabinol (THC) as a potential therapeutic agent for Alzheimer’s. The patent claims discovery of a new pathway in which low doses of THC bind to amyloid beta plaques and prevent those plaques from aggregating on neurons, which is exactly what occurs in Alzheimer’s disease and causes cognitive decline.

This new pathway holds immense potential in treating Alzheimer’s, and IGC will own the rights to this unprecedented therapeutic pathway if the patent is granted and proven. Acquiring this patent further supports IGC in protecting its proprietary formulation IGC-AD1, which includes low-doses of THC and is intended to disrupt the buildup of amyloid beta plaques and alleviate some of the worst symptoms of Alzheimer’s disease.

Several clinical studies are currently underway to address the ravages of Alzheimer’s, but later this year IGC will become the first and only company to utilize cannabis-based therapies for the treatment of the disease. Even though there are about a dozen publicly traded cannabis pharmaceutical stocks on the market, none have patent filings to a potential Alzheimer’s breakthrough.

Should IGC’s clinical studies show promise on Alzheimer’s or any of its primary pipeline of phytocannabinoid therapeutics, it could not only trigger a major shift in national medical marijuana policy but also dramatically impact the company’s market capitalization and stock price to the upside.

For more information, please visit http://www.igcinc.us